Repros Therapeutics Inc. (NASDAQ:RPRX) saw unusually-high trading volume on Tuesday . Approximately 1,252,343 shares changed hands during mid-day trading, an increase of 55% from the previous session’s volume of 806,506 shares.The stock last traded at $0.35 and had previously closed at $0.31.

Separately, Laidlaw downgraded shares of Repros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, July 21st.

The firm has a 50-day moving average of $0.32 and a 200-day moving average of $0.68. The firm’s market capitalization is $12.41 million.

Repros Therapeutics (NASDAQ:RPRX) last posted its earnings results on Monday, August 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.14. The business had revenue of $0.01 million for the quarter. Repros Therapeutics had a negative net margin of 56,062.07% and a negative return on equity of 412.64%. Analysts expect that Repros Therapeutics Inc. will post ($1.07) EPS for the current fiscal year.

A hedge fund recently raised its stake in Repros Therapeutics stock. Allegis Investment Advisors LLC lifted its holdings in Repros Therapeutics Inc. (NASDAQ:RPRX) by 8.9% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 398,792 shares of the biotechnology company’s stock after purchasing an additional 32,602 shares during the period. Allegis Investment Advisors LLC owned about 1.49% of Repros Therapeutics worth $183,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 14.52% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Repros Therapeutics Inc. (RPRX) Sees Unusually-High Trading Volume” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at

About Repros Therapeutics

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Receive News & Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related companies with's FREE daily email newsletter.